ECG Software & EKG Management @ CardioComm Solutions, Inc. - Arrhythmia EKG Management, 12 Lead ECG Management, ECG Software, Web Based ECG, EKG software
CardioComm Solutions, Inc

CardioComm Press Releases
News & Media


May 14, 2015

CardioComm Solutions Optimized for HeartCheck™ and GEMS WIN Sale and Operations with ISO Certification Award

Consolidated Resources will Better Serve HeartCheck™, GEMS™ WIN and New Product Sales.

TORONTO, ONTARIO - CardioComm Solutions, Inc. (TSX VENTURE:EKG) (“CardioComm Solutions” or the “Company”) today confirmed it has received new regulatory certification from the Canadian Medical Devices Conformity Assessment System (CMDCAS) specifically for its Toronto facilities. Global Business/Product Development, Regulatory, Quality, Development, Service and Sales Systems will now be based out of the Company's Toronto location.

Securing ISO audit and EC-Certification will permit more efficient and cost effective marketing and sales support for CardioComm Solutions' flagship products, the HeartCheck™ ECG devices and GEMS™ WIN (Global ECG Management Solution for Windows 7). With operations, sales and product development in one location, the Company will also be positioned to respond optimally to growing GEMS™ WIN sales and installation requests and GEMS™ WIN custom software engineering projects.

With product engineering, testing and quality auditing occurring at the same location, the Company's capacity for meeting expanding applications for use of the HeartCheck™ devices, GEMS™ Home and the announced plans for a wireless HeartCheck™ device for Smartphone connectivity will also be strengthened.

The Company also confirms it will now close its Victoria location, which will provide operational and maintenance cost savings. A review of the CardioComm Solutions' 2014 financial statements show a progressive reduction in overhead expenses, which will be further reduced with all corporate activities amalgamated into one location.

CardioComm Solutions is registered under Health Canada's Therapeutic Products Programme (TPP) according to ISO 13485:2003 and CMDCAS as well as MDD regulations, for the Manufacturing and Distribution of Health Management Software Systems and Distribution of Health Monitoring Devices. The mission of the TPP, and the purpose of the audit, is to ensure that drugs, medical devices, and other therapeutic products available in Canada are safe, effective and are of high quality.

CardioComm Solutions has for several years received such clearances through its Victoria, BC, location which audit: Management Reviews, Procedures; Corrective Action Loops, Production and Process Controls; Customer Related Processes; Implementation of Applicable Canadian Medical Devices Regulations - Part 1 Requirements; Implementation of Regulatory Requirements of the Directive 93/42/EEC; and Document Control Processes. The audit concluded that CardioComm Solutions' Toronto location has fulfilled the requirements of all applicable ISO 13485:2003 standards as well as Canadian regulatory requirements.

More information about the Company and its products and services can be found at

download pdf

About CardioComm Solutions
CardioComm Solutions' patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms (ECGs) for diagnosis and management of cardiac patients.  Products are sold worldwide through a combination of an external distribution network and a North American-based sales team.  The Company has earned the ISO 13485 certification, is HPB approved, HIPAA compliant, and has received FDA market clearance for its software devices.  CardioComm Solutions is headquartered in Toronto, Canada, with offices in Victoria, B.C.  


Etienne Grima, Chief Executive Officer

Forward-looking statements

This release may contain certain forward-looking statements and forward looking information with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items. Such statements and information reflect management's current beliefs and are based on information currently available to management. By their nature, forward-looking statements and forward-looking information involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements and forward-looking information.

In evaluating these statements, readers should: specifically consider risks discussed under the heading "Risk Factors" in the Company's Annual Information Form, available at; not to place undue reliance on forward-looking statements and forward-looking information; be aware. the Company does not assume any obligation to update the forward-looking statements and forward-looking information contained in this Annual Information Form other than as required by applicable laws (including without limitation Section 5.8(2) of National Instrument 51-102 (Continuous Disclosure Obligations).

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


Investor Information
GE Healthcare Notice to MARS® Event Customers

Arrhythmia EKG Management | 12 Lead ECG Management | ECG Software | EKG Management | Web Based ECG | EKG Software